News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Batu Biologics Strategy For FDA Approval Of Lung Cancer Immunotherapy Featured In San Diego Business Journal


7/28/2014 9:38:12 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SAN DIEGO--(BUSINESS WIRE)--Batu Biologics announced today that it’s President and CEO, Samuel C. Wagner, was featured in the weekly business publication, the San Diego Business Journal. The article, which was published in the July 21st edition, discussed the company’s strategy in developing its immunotherapeutic lung cancer vaccine, ValloVax, for which FDA Investigational New Drug (IND) submission is planned in Q1 of 2015.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES